All Dose Levels, Cycle 1
Name	NC/NA, %	Grade 1, %	Grade 2, %	Grade 3, %	Grade 4, %	Grade 5, %	All grades, %
Diarrhea	67	17	11	6	0	0	33
Palmar‐plantar erythrodysesthesia syndrome	50	17	28	6	0	0	50
Pain of skin	83	0	11	6	0	0	17
Rash maculo‐papular	89	6	6	0	0	0	11
Lower gastrointestinal hemorrhage	94	0	6	0	0	0	6
Abdominal pain	94	0	6	0	0	0	6
Back pain	94	0	6	0	0	0	6
Proteinuria	94	0	6	0	0	0	6
Hearing impaired	94	6	0	0	0	0	6
Insomnia	94	0	6	0	0	0	6
Neutrophil count decreased	94	0	6	0	0	0	6
Hematuria	89	11	0	0	0	0	11
Aspartate aminotransferase increased	78	17	0	6	0	0	22
Alanine aminotransferase increased	78	11	6	6	0	0	22
Blood bilirubin increased	83	6	0	11	0	0	17
Electrocardiogram QT corrected interval prolonged	78	11	11	0	0	0	22
Anorexia	78	11	11	0	0	0	22
Hypoglossal nerve disorder	83	17	0	0	0	0	17
Fatigue	83	17	0	0	0	0	17
Hypertension	83	17	0	0	0	0	17
White blood cell decreased	89	0	11	0	0	0	11
Platelet count decreased	89	0	11	0	0	0	11
Palpitations	89	11	0	0	0	0	11
Hemorrhoids	89	11	0	0	0	0	11
Mucositis oral	89	11	0	0	0	0	11
Vomiting	89	6	6	0	0	0	11
Nausea	89	11	0	0	0	0	11
Fever	89	11	0	0	0	0	11
Hypokalemia	89	11	0	0	0	0	11
Pain in extremity	89	11	0	0	0	0	11
Palmar‐plantar erythrodysesthesia syndrome	40	30	20	10	0	0	60
Pain of skin	70	10	10	10	0	0	30
Rash maculo‐papular	90	0	10	0	0	0	10
Circumoral numbness	80	20	0	0	0	0	20
Edema limbs	90	10	0	0	0	0	10
Diarrhea	60	10	20	10	0	0	40
Abdominal pain	80	20	0	0	0	0	20
Anorexia	90	0	10	0	0	0	10
Dysphagia	90	10	0	0	0	0	10
Constipation	90	10	0	0	0	0	10
Blood bilirubin increased	80	0	10	10	0	0	20
Aspartate aminotransferase increased	70	10	10	10	0	0	30
Alanine aminotransferase increased	60	20	10	10	0	0	40
Hypertension	90	0	10	0	0	0	10
Platelet count decreased	80	0	20	0	0	0	20
Anemia	90	0	10	0	0	0	10
Fatigue	90	0	10	0	0	0	10
Fever	90	10	0	0	0	0	10

Adverse Events Legend

Treatment‐related adverse events of patients in the first cycle (n = 18). Abbreviation: NC/NA, no change from baseline/no adverse event.